{"id":51396,"date":"2025-12-19T14:06:59","date_gmt":"2025-12-19T06:06:59","guid":{"rendered":"https:\/\/flcube.com\/?p=51396"},"modified":"2025-12-19T14:07:00","modified_gmt":"2025-12-19T06:07:00","slug":"rona-therapeutics-sirna-rn5681-submitted-to-australian-ethics-committee","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51396","title":{"rendered":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee"},"content":{"rendered":"\n<p><strong>Rona Therapeutics<\/strong> announced the submission of <strong>RN5681<\/strong> to the <strong>Australian Human Research Ethics Committee (HREC)<\/strong>, advancing the company&#8217;s first bi\u2011valent <strong>siRNA<\/strong> into clinical development. The <strong>Phase\u202f1<\/strong> trial is expected to begin dosing in <strong>Q1\u202f2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-amp-regulatory-milestone\">Clinical Development &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Rona Therapeutics<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>RN5681<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>Submitted to Australian HREC<\/td><\/tr><tr><td><strong>Clinical Trial<\/strong><\/td><td>Phase\u202f1 initiation targeted for Q1\u202f2026<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>GalNAc\u2011conjugated, dual\u2011targeting siRNA<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>Dual\u2011Target Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targets<\/strong>: <strong>PCSK9<\/strong> and <strong>LPA<\/strong> (lipoprotein(a))<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Simultaneously silences both genes to lower LDL\u2011C and reduce Lp(a) levels<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses two genetically validated, complementary drivers of <strong>atherosclerotic cardiovascular disease (ASCVD)<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Key Advantages:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unified therapy<\/strong>: Combines LDL\u2011C lowering and Lp(a) reduction in a single molecule<\/li>\n\n\n\n<li><strong>Deep, durable lipid improvement<\/strong>: siRNA technology provides long\u2011lasting effect<\/li>\n\n\n\n<li><strong>Residual risk<\/strong>: Targets persistent cardiovascular risk not resolved by statins or existing PCSK9 inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Market Parameter<\/th><th>Insight<\/th><\/tr><\/thead><tbody><tr><td><strong>ASCVD Burden<\/strong><\/td><td>Leading cause of death globally; 18 million deaths annually<\/td><\/tr><tr><td><strong>Lp(a) Elevation<\/strong><\/td><td>Affects 20\u201130% of population; independent cardiovascular risk factor<\/td><\/tr><tr><td><strong>PCSK9 Market<\/strong><\/td><td>Global market $10+ billion; injectable antibodies dominate<\/td><\/tr><tr><td><strong>Competitive Gap<\/strong><\/td><td>No approved therapy simultaneously targets PCSK9 and Lp(a)<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>High\u2011risk patients require multiple therapies; single\u2011agent convenience critical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sirna-technology-amp-innovation\">siRNA Technology &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GalNAc Conjugation<\/strong>: Enables liver\u2011specific delivery with subcutaneous administration<\/li>\n\n\n\n<li><strong>Bivalent Design<\/strong>: First dual\u2011targeting siRNA to enter clinical development<\/li>\n\n\n\n<li><strong>Dosing Convenience<\/strong>: Potential for quarterly or semi\u2011annual dosing vs. monthly injections<\/li>\n\n\n\n<li><strong>Pipeline Position<\/strong>: Lead asset in Rona&#8217;s cardio\u2011metabolic franchise<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding RN5681 development timelines, clinical outcomes, and market potential. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-51396","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company&#039;s first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51396\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee\" \/>\n<meta property=\"og:description\" content=\"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company&#039;s first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51396\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-19T06:06:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-19T06:07:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee\",\"datePublished\":\"2025-12-19T06:06:59+00:00\",\"dateModified\":\"2025-12-19T06:07:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1901.webp\",\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51396#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51396\",\"name\":\"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1901.webp\",\"datePublished\":\"2025-12-19T06:06:59+00:00\",\"dateModified\":\"2025-12-19T06:07:00+00:00\",\"description\":\"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51396\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51396#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee - Insight, China&#039;s Pharmaceutical Industry","description":"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51396","og_locale":"en_US","og_type":"article","og_title":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee","og_description":"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.","og_url":"https:\/\/flcube.com\/?p=51396","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-19T06:06:59+00:00","article_modified_time":"2025-12-19T06:07:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51396#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51396"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee","datePublished":"2025-12-19T06:06:59+00:00","dateModified":"2025-12-19T06:07:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51396"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51396#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51396#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51396","url":"https:\/\/flcube.com\/?p=51396","name":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51396#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51396#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","datePublished":"2025-12-19T06:06:59+00:00","dateModified":"2025-12-19T06:07:00+00:00","description":"Rona Therapeutics announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi\u2011valent siRNA into clinical development. The Phase\u202f1 trial is expected to begin dosing in Q1\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51396#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51396"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51396#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","width":1080,"height":608,"caption":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51396#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51396"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51396\/revisions"}],"predecessor-version":[{"id":51521,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51396\/revisions\/51521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51520"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}